Johnson & Johnson to challenge Novartis in axial spondyloarthrtis treatment space; report

23 July 2015

US health care giant Johnson & Johnson’s (NYSE: JNJ) psoriasis drug, Stelara (ustekinumab), has progressed into Phase III development for axial spondyloarthritis (axSpA) and, following its anticipated approval, is forecast to achieve impressive axSpA sales of $244.7 million in 2024,

According to research and consulting firm GlobalData’s latest report, Stelara, an Interleukin12/IL23 inhibitor, has demonstrated a strong safety profile in other indications, and is expected to launch in the USA and five European countries (France, Germany, Italy, Spain, and the UK) for the treatment of ankylosing spondylitis (AS) in first-half 2020 and non-radiographic axial spondyloarthritis (nr-axSpA) in H1 2021.

According to Heather Leach, GlobalData’s senior analyst covering immunology, the anticipated launches of Swiss pharma giant Novartis’ (NOVN: VX) Cosentyx (secukinumab), an IL17 inhibitor, and J&J’s Stelara will add new mechanisms of action (MoAs) to the existing axSpA treatment space.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK